Drugs to Decrease Alcohol Drinking

References

• Holden C. Alcoholism and the medical cost crunch. Science 1987; 235: 1132–3
   PubMed Web of Science ®Google Scholar
• Sinclair J D. The feasibility of effective psychopharmacological treatments for alcoholism. Br J Addict 1987; 82: 1213–23
   PubMedGoogle Scholar
• Sinclair J D. Lithium-induced suppression of alcohol drinking by rats. Med Biol 1974; 52: 133–6
   PubMedGoogle Scholar
• Sinclair J D. Ethanol intake and lithium in rats. Alcoholism and affective disorders, D W. Goodwin, C K. Erickson. Spectrum, Jamaica, N.Y. 1979; 261–83
   Google Scholar
• Kline N S., Wren J C., Cooper T B., Varga E, Canal O. Evaluation of lithium-therapy in chronic and periodic alcoholism. Am J Med Sci 1974; 268: 15–22
   PubMed Web of Science ®Google Scholar
• Clark D C., Fawcett J. Does lithium carbonate therapy for alcoholism deter relapse drinking?. Recent Dev Alcohol 1989; 7: 315–28
   PubMedGoogle Scholar
• Dorus W, Ostrow D G., Anton R, et al. Lithium treatment of depressed and nondepressed alcoholics. JAMA 1989; 262: 1646–52
   PubMed Web of Science ®Google Scholar
• Merry J, Reynolds C M., Bailey J, Coppen A. Prophylactic treatment of alcoholism by lithium carbonate; a controlled study. Lancet 1976; ii: 481–2
   Google Scholar
• Fawcett J, Clark D C., Aagesen C A., et al. A double-blind, placebo-controlled trial of lithium carbonate therapy for alcoholism. Arch Gen Psychiatry 1987; 44: 248–56
   PubMed Web of Science ®Google Scholar
• Judd L L., Huey L Y. Lithium antagonizes ethanol intoxication in alcoholics. Am J Psychiatry 1984; 141: 1517–21
   PubMed Web of Science ®Google Scholar
• Feldman H. Apomorphine in the treatment of alcohol addiction: Neurophysiological and therapeutic aspects. Psychiatr J Univ Ottawa 1983; 8: 30–7
   PubMedGoogle Scholar
• Anokhina I P. Dopamine receptor agonists in the treatment of alcoholism. Pharmacological treatments for alcoholism, G Edwards, J Littleton. Crook Helm, London 1984; 145–51
   Google Scholar
• Fadda F, Franch F, Mosca E, Meloni R, Gessa G L. Inhibition of voluntary ethanol intake in rats by a combination of dihydroergotoxine and thioridazine. Alcohol Drug Res 1987; 7: 285–90
   PubMedGoogle Scholar
• Amit Z, Sutherland E A., Gill K, Ogren S-O. Zimeldine: A review of its effects on ethanol consumption. Neurosci Biobehav Rev 1984; 8: 35–54
   PubMed Web of Science ®Google Scholar
• Naranjo C A., Seller E M., Roach C A., Woodley D V., Sanchez-Craig M, Sykora K. Zimelidine-induced variation in alcohol intake in nondepressed heavy drinkers. Clin Pharmacol 1984; 35: 374–81
   Google Scholar
• Naranjo C A., Sellers E M., Lawrin M O. Modulation of ethanol intake by serotonin uptake inhibitors. J Clin Psychiatry 1986; 47(suppl 4)16–22
   PubMed Web of Science ®Google Scholar
• Fuller R K., Branchey L, Brightwell D R., et al. Disulfiram treatment of alcoholism: A Veterans Administration Cooperative Study. JAMA 1986; 256: 1449–55
   PubMed Web of Science ®Google Scholar
• Siegel S. Alcohol and opiate dependence: Re-evaluation of the Victorian perspective. Research advances in alcohol and drug problems, H D. Cappell, F B. Glaser, Y Israel, et al. Plenum Publishing Corp., New York 1986; Vol. 9: 279–314
   Google Scholar
• Teeling-Smith G. Pharmacological treatments for alcohol problems as a challenge to pharmaceutical innovation. Pharmacological treatments for alcoholism, G Edwards, J Littleton. Croom Helm, London 1984; 35–45
   Google Scholar
• Sinclair J D., Adkins J, Walker S. Morphine-induced suppression of voluntary alcohol drinking in rats. Nature 1973; 246: 425–7
   PubMed Web of Science ®Google Scholar
• Linseman M A. Central vs. peripheral mediation of opioid effects on alcohol consumption in free-feeding rats. Pharmacol Biochern Behav 1989; 33: 407–13
   PubMed Web of Science ®Google Scholar
• Sinclair J D. Method for treating alcoholism by extinguishing the alcohol-drinking response. US Patent 4, 882, 335, 1989, Nov. 21
   Google Scholar
• Tepperman F S., Hirst M, Smith P. Brain and serum levels of naloxone following peripheral administration. Life Sci 1983; 33: 1091–6
   PubMed Web of Science ®Google Scholar
• Hyytiä P, Sinclair J D. Differential reinforcement and diurnal rhythms of lever pressing for ethanol in AA and Wistar rats. Alcoholism: Clin Exp Res 1990; 14: 375–9
   PubMed Web of Science ®Google Scholar
• Renault P F. Treatment of heroin-dependent persons with antagonists: Current status. Narcotic Antagonists: Naltrexone Pharmacochemistry and Sustained-Release Preparations, R Willette, G Barnett. NIDA Research Monograph No. 28, U.S. Government Printing Office, Washington 1981; 11–22
   Google Scholar
• Volpicelli J R., O'Brien C P., Alterman A I., Hayashida M. Naltrexone and the treatment of alcohol dependence: Initial observations. Opioids, bulimia, and alcohol abuse & alcoholism, L D. Reid. Springer-Verlag, New York 1990; 195–214
   Google Scholar
• Blum K, Trachtenberg N IC. Alcoholism: Scientific basis of a neuropsychogenetic disease. Int J Addict 1988; 23: 781–96
   PubMed Web of Science ®Google Scholar
• Davis W M., Smith S G. Naloxone use to eliminate opiateseeking behavior: Need for extinction of conditioned reinforcement. Biol Psychiatry 1974; 9: 181–9
   PubMed Web of Science ®Google Scholar
• Trujillo K A., Belluzzi J D., Stein L. Opiate antagonists and self-stimulation: extinction-like response patterns suggest selective reward deficit. Brain Res 1989; 492: 15–28
   PubMed Web of Science ®Google Scholar
• Bain G T., Kornetsky C. Ethanol oral self-administration and rewarding brain stimulation. Alcohol 1989; 6: 499–503
   PubMed Web of Science ®Google Scholar
• Rankin H, Hodgson R, Stockwell T. The concept of craving and its measurement. Behav Res Ther 1979; 17: 389–96
   PubMed Web of Science ®Google Scholar